Sunifiram (Hungarian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sunifiram" in Hungarian language version.

refsWebsite

Global rank Hungarian rank

21nih.gov

4^th place

11^th place

19doi.org

2^nd place

8^th place

1archive.org

6^th place

14^th place

archive.org

(1993) „Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats”. Life sciences 53 (24), 1821–1832. o. DOI:10.1016/0024-3205(93)90490-T. PMID 8246681.

doi.org

dx.doi.org

(2002) „DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer”. Naunyn-Schmiedeberg's archives of pharmacology 365 (6), 419–426. o. DOI:10.1007/s00210-002-0577-3. PMID 12070754.
(2006) „Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers”. CNS Drug Reviews 12 (1), 39–52. o. DOI:10.1111/j.1527-3458.2006.00039.x. PMID 16834757.
(2004) „Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs”. Bioorganic & Medicinal Chemistry 12 (1), 71–85. o. DOI:10.1016/j.bmc.2003.10.025. PMID 14697772.
(2008) „Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers”. Bioorganic & Medicinal Chemistry 16 (3), 1431–1443. o. DOI:10.1016/j.bmc.2007.10.050. PMID 17981042.
(2008) „Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators”. Bioorganic & Medicinal Chemistry 16 (23), 10034–10042. o. DOI:10.1016/j.bmc.2008.10.017. PMID 18954993.
(2003) „AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)”. Naunyn-Schmiedeberg's archives of pharmacology 368 (6), 538–545. o. DOI:10.1007/s00210-003-0812-6. PMID 14600801.
(2013) „Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine binding site of N-methyl-D-aspartate receptor”. Hippocampus. DOI:10.1002/hipo.22150. PMID 23733502.
(2013) „Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice”. Behavioural Brain Research 242, 150–157. o. DOI:10.1016/j.bbr.2012.12.054. PMID 23295391.
(1993) „Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats”. Life sciences 53 (24), 1821–1832. o. DOI:10.1016/0024-3205(93)90490-T. PMID 8246681.
(2000) „Molecular simplification of 1,4-diazabicyclo4.3.0nonan-9-ones gives piperazine derivatives that maintain high nootropic activity”. Journal of medicinal chemistry 43 (23), 4499–4507. o. DOI:10.1021/jm000972h. PMID 11087574.
(2008) „CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region”. Journal of neurochemistry 106 (3), 1092–1103. o. DOI:10.1111/j.1471-4159.2008.05440.x. PMID 18445137.
(2010) „Lithium acts as a potentiator of AMPAR currents in hippocampal CA1 cells by selectively increasing channel open probability”. The Journal of Physiology 588 (20), 3933–3941. o. DOI:10.1113/jphysiol.2010.195115. PMID 20807790. PMC 3000583.
(2012) „Effects of 4-weeks of treatment with lithium and olanzapine on long-term potentiation in hippocampal area CA1”. Neuroscience Letters 524 (1), 5–9. o. DOI:10.1016/j.neulet.2012.06.047. PMID 22750162.
(2003) „Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus”. Journal of neurochemistry 85 (4), 872–881. o. DOI:10.1046/j.1471-4159.2003.01725.x. PMID 12716419.
(2012) „Lithium: A switch from LTD- to LTP-like plasticity in human cortex”. Neuropharmacology 63 (2), 274–279. o. DOI:10.1016/j.neuropharm.2012.03.023. PMID 22507665.
(2003) „Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: A role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity”. FEBS letters 538 (1–3), 145–148. o. DOI:10.1016/S0014-5793(03)00167-4. PMID 12633868.
(1999) „Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity”. The Journal of biological chemistry 274 (10), 6039–6042. o. DOI:10.1074/jbc.274.10.6039. PMID 10037682.
(1998) „Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx”. Proceedings of the National Academy of Sciences of the United States of America 95 (5), 2642–2647. o. DOI:10.1073/pnas.95.5.2642. PMID 9482940. PMC 19446.
(2002) „Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation”. Journal of neurochemistry 80 (4), 589–597. o. DOI:10.1046/j.0022-3042.2001.00728.x. PMID 11841566.

nih.gov

pubmed.ncbi.nlm.nih.gov

(2002) „DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer”. Naunyn-Schmiedeberg's archives of pharmacology 365 (6), 419–426. o. DOI:10.1007/s00210-002-0577-3. PMID 12070754.
(2006) „Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers”. CNS Drug Reviews 12 (1), 39–52. o. DOI:10.1111/j.1527-3458.2006.00039.x. PMID 16834757.
(2004) „Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs”. Bioorganic & Medicinal Chemistry 12 (1), 71–85. o. DOI:10.1016/j.bmc.2003.10.025. PMID 14697772.
(2008) „Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers”. Bioorganic & Medicinal Chemistry 16 (3), 1431–1443. o. DOI:10.1016/j.bmc.2007.10.050. PMID 17981042.
(2008) „Design, synthesis and preliminary pharmacological evaluation of new analogues of DM232 (unifiram) and DM235 (sunifiram) as cognition modulators”. Bioorganic & Medicinal Chemistry 16 (23), 10034–10042. o. DOI:10.1016/j.bmc.2008.10.017. PMID 18954993.
(2003) „AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)”. Naunyn-Schmiedeberg's archives of pharmacology 368 (6), 538–545. o. DOI:10.1007/s00210-003-0812-6. PMID 14600801.
(2013) „Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine binding site of N-methyl-D-aspartate receptor”. Hippocampus. DOI:10.1002/hipo.22150. PMID 23733502.
(2013) „Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice”. Behavioural Brain Research 242, 150–157. o. DOI:10.1016/j.bbr.2012.12.054. PMID 23295391.
(1993) „Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats”. Life sciences 53 (24), 1821–1832. o. DOI:10.1016/0024-3205(93)90490-T. PMID 8246681.
(2000) „Molecular simplification of 1,4-diazabicyclo4.3.0nonan-9-ones gives piperazine derivatives that maintain high nootropic activity”. Journal of medicinal chemistry 43 (23), 4499–4507. o. DOI:10.1021/jm000972h. PMID 11087574.
(2008) „CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region”. Journal of neurochemistry 106 (3), 1092–1103. o. DOI:10.1111/j.1471-4159.2008.05440.x. PMID 18445137.
(2010) „Lithium acts as a potentiator of AMPAR currents in hippocampal CA1 cells by selectively increasing channel open probability”. The Journal of Physiology 588 (20), 3933–3941. o. DOI:10.1113/jphysiol.2010.195115. PMID 20807790. PMC 3000583.
(2012) „Effects of 4-weeks of treatment with lithium and olanzapine on long-term potentiation in hippocampal area CA1”. Neuroscience Letters 524 (1), 5–9. o. DOI:10.1016/j.neulet.2012.06.047. PMID 22750162.
(2003) „Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus”. Journal of neurochemistry 85 (4), 872–881. o. DOI:10.1046/j.1471-4159.2003.01725.x. PMID 12716419.
(2012) „Lithium: A switch from LTD- to LTP-like plasticity in human cortex”. Neuropharmacology 63 (2), 274–279. o. DOI:10.1016/j.neuropharm.2012.03.023. PMID 22507665.
(2003) „Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: A role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity”. FEBS letters 538 (1–3), 145–148. o. DOI:10.1016/S0014-5793(03)00167-4. PMID 12633868.
(1999) „Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity”. The Journal of biological chemistry 274 (10), 6039–6042. o. DOI:10.1074/jbc.274.10.6039. PMID 10037682.
(1998) „Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx”. Proceedings of the National Academy of Sciences of the United States of America 95 (5), 2642–2647. o. DOI:10.1073/pnas.95.5.2642. PMID 9482940. PMC 19446.
(2002) „Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation”. Journal of neurochemistry 80 (4), 589–597. o. DOI:10.1046/j.0022-3042.2001.00728.x. PMID 11841566.

ncbi.nlm.nih.gov

(2010) „Lithium acts as a potentiator of AMPAR currents in hippocampal CA1 cells by selectively increasing channel open probability”. The Journal of Physiology 588 (20), 3933–3941. o. DOI:10.1113/jphysiol.2010.195115. PMID 20807790. PMC 3000583.
(1998) „Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx”. Proceedings of the National Academy of Sciences of the United States of America 95 (5), 2642–2647. o. DOI:10.1073/pnas.95.5.2642. PMID 9482940. PMC 19446.